Radiopharm Theranostics Announces Updated Clinical Results From First Two Patients In Third Cohort Of RAD204; First RECIST-Confirmed Durable Partial Response At Current Highest Dose Level #3, With Patient Progression Free Beyond Seven Months
Second patient dosed remains progression free on treatment with RAD204 with early tumor shrinkage observed after first treatmentRAD204 is generally well-tolerated with no dose-limiting toxicities observed in any of the
A medicine company tested a new cancer drug on a few patients and saw good early signs—one patient's tumors shrank and stayed smaller for over seven months, with no serious side effects so far. When you look at this stock, watch whether more patients in future tests show similar results, since early success with just two people doesn't guarantee the drug will work for everyone.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.